Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…Abstract Number: 740 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Mycophenolate Mofetil Therapy in a Systemic Lupus Erythematosus Cohort: A Multi-Factorial Assessment
Background/Purpose: Lack of adherence to treatment recommendations is a serious confounder to assessment of treatment efficacy for systemic lupus erythematosus (SLE). Estimates of nonadherence with…Abstract Number: 1824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Use Associates with Unique Biologic Changes in B Cell and T Regulatory Cell Pathways in SLE Patients
Background/Purpose: The management of systemic lupus erythematosus (SLE) is complicated by a heterogeneous clinical presentation. Currently, mycophenolate mofetil (MMF) is a commonly used medication to…Abstract Number: 724 • 2015 ACR/ARHP Annual Meeting
Mycophenolate Mofetil in Non-Renal Manifestations of Systemic Lupus Erythematosus. an Observational Cohort Study
Background/Purpose: Mycophenolate mofetil (MMF), along with corticosteroids, is considered as the standard of care in lupus nephritis (LN); however, its efficacy in extra-renal manifestations of…Abstract Number: 2937 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns Differ Based on Age of Systemic Lupus Erythematosus Onset: A Comparison of Azathioprine and Mycophenolate on the Prevention of Lupus Nephritis
Background/Purpose: Lupus nephritis (LN) is a major cause of morbidity and mortality among patients with systemic lupus erythematous (SLE). Studies have demonstrated efficacy and safety…Abstract Number: 1804 • 2013 ACR/ARHP Annual Meeting
Effect of Mycophenolate On the White Blood Cell Count and the Frequency of Infection in Systemic Lupus Erythematosus
Background/Purpose: Leukopenia is a common manifestation of SLE. Addition of immunosuppressive therapy is of concern, in that it could worsen leukopenia; increase the risk of…